Third Time Lucky? Eli Lilly and Eisai Get Another Shot At English Funding For Alzheimer’s Drugs

 
• By Neena Brizmohun

Cost and evidence gaps remain barriers for Kisunla and Leqembi as NICE rejects the drugs again but opens further consultations on the reimbursement of the Alzheimer's disease-modifying treatments.

Dementia and Parkinson's disease, ADHD, composition for head disease theme, space for text
Lilly and Eisai still need to convince NICE that their Alzheimer's disease drugs are cost effective (Shutterstock)

More from Health Technology Assessment

More from Geography